ProxyMiner Toolkit

ProxyMiner / Company

ZIMMER BIOMET HOLDINGS, INC.ZBH

Latest proxy: 2026 · view on SEC ↗ · CIK 0001136869

↓ Export PDF
← All companies

CEO total pay

$16,106,550

Ivan Tornos · 2025

Say on pay

95%

Latest disclosed shareholder vote

CEO pay ratio

Item 402(u)

200 to 1

Median employee: $80,380

Compensation committee

Committee Report

Compensation and Management Development Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
Ivan Tornos2025 compensation
Chairman, President and CEO
$16,106,550↑ 7%
90% at-risk
$1,281,846$12,000,101$2,420,767$403,836
Suketu Upadhyay2025 compensation
CFO and EVP - Finance
$6,211,805↑ 6%
83% at-risk
$906,780$4,000,104$1,141,636$163,284
Jehanzeb Noor2025 compensation
Named executive officer
$7,874,209
91% at-risk
$683,000$5,100,212$730,913$27,409
Kevin Thornal2025 compensation
Named executive officer
$6,210,746
93% at-risk
$405,385$5,300,085$505,275—
Wilfred van Zuilen2025 compensation
Group President, EMEA
$4,139,409↑ 19%
76% at-risk
$743,149$2,000,052$730,333$112,372

Pay mix: base cash incentive equity other

Add to peer comparison →Year-over-year diff →

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

EXECUTIVE SUMMARY 2025 NEOs This CD&A describes the compensation of the following NEOs for 2025: NEO Title Ivan Tornos Chairman, President and Chief Executive Officer Suketu Upadhyay Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain Kevin Thornal Group President, Global Businesses and the Americas Jehanzeb Noor Senior Vice President, Chief Strategy, Business Development, Innovation and Transformation Officer Wilfred van Zuilen Group President, Europe, Middle East and Africa (“EMEA”) Our 2025 Results and Executive Compensation Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or i…

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • hedging

    prohibited

    “Prohibition on Hedging and Pledging”

  • pledging

    prohibited

    “Prohibition on Hedging and Pledging”

  • clawback

    present

    “Clawback Policy”), in compliance with the listing standards of the New York Stock Exchange”

  • stock ownership guidelines

    present

    “stock ownership guidelines”

  • change in control

    Employment and Change in Control Severance Agreements

    “Employment and Change in Control Severance Agreements”

  • compensation consultant

    independent

    “independent compensation consultant”

  • compensation committee

    Compensation and Management Development Committee

    “Compensation and Management Development Committee”

Performance markers

Metric facts

  • median employee compensation

    $80,380

    “We then identified our median employee from the Median Group as an employee whose annual total compensation includes elements that we reasonably believe reflect our compensation practices for a representative employee. A…”

  • ceo pay ratio

    200 to 1

    “2025 CEO Pay Ratio As required by Item 402(u) of Regulation S-K of the Exchange Act, we are providing the following information about the relationship of the annual total compensation of our CEO and the annual total comp…”

  • revenue

    $1.0 million

    ““CORPORATE GOVERNANCE - STOCK TRADING POLICY AND PROHIBITION ON PLEDGING AND HEDGING.” Tax Deductibility of Executive Compensation The committee views the tax deductibility of compensation as one of many factors to be co…”

  • annual incentive payout

    124.6%

    “on under his leadership, the committee determined it was appropriate to decrease his payout by $5,104, reflecting 90% achievement of his individual performance goals and resulting in a total payout under the 2025 annual …”

  • time equity mix

    —

    “The value of long shares and time-based RSUs is counted toward these guidelines.”

  • say on pay

    95%

    “At our 2025 annual meeting of shareholders, approximately 95% of votes cast were in favor of our Say on Pay proposal.”

Ask

Anything about ZIMMER BIOMET HOLDINGS, INC.’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…